Dish of the day
No Joiners Today
Off the menu
PME African Infrastructure Opportunities has left AIM
What’s cooking in the IPO kitchen?
The cupboards are bare!
SRT Marine Systems 32p £51.9m (AIM:SRT)
The global provider of maritime surveillance, vessel tracking, monitoring, management and safety systems, has completed its COVID-19 resilience financing, raising a total of £5.3m of cash in a combination of loans and equity.
On 7 April 2020, the Company announced that it had raised an aggregate of £2.8m from investors. We can now announce that the Company has agreed an additional £2.5m loan facility provided by its main bank, bringing the total raised to £5.3m. The bank loan is being provided with the support of the UK government Coronavirus Business Interruption Loan Scheme (CBILS) and as such is interest and fee free and repayable in one year.
Begbies Traynor 89.5p £114.3m (AIM:BEG)
Latest Red Flag Alert Report for Q1 2020
Coronavirus pushes financially distressed companies over the half-million mark
· Number of businesses in significant distress stands at 509,000 – the highest number measured by the Red Flag Alert research
· Impact of coronavirus lockdown sees the largest quarterly increase since the end of 2017 – 15,000 more businesses in significant distress (3%) since Q4 2019
· Record figure likely to be the tip of the iceberg, as full Covid-19 impact will build through Q2
· Number of critically distressed companies jumps 10% in the last quarter
Tungsten Corp 28.5p £35.9m (AIM:TUNG)
The global electronic invoicing and purchase order transactions network announced that Chris Allen will be joining the Board as Chief Financial Officer on 27th April 2020.
As CFO, UK & Europe at Worldpay plc Chris provided finance leadership of the market leading UK business unit. His role was expanded to a wider European brief following the acquisition of Worldpay by Vantiv Inc in January 2018. During this period he ran a complex turnaround of a now profitable £1.3bn revenue business within Worldpay. Prior to this, he was Finance Director at NOW TV; Finance Director at LoveFilm International and Investor Relations and Corporate Finance Manager at BSKYB plc.
Hutchison China Med 323.5p £2.2bn (AIM:HCM)
The U.S. Food and Drug Administration has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors (“NET”) and extra-pancreatic (non-pancreatic) NET in patients who are not amenable for surgery.
Blues Star Capital 0.11p £3.5m (AIM:BLU)
The Company has raised £100,000 at a price of 0.1p per ordinary share. The investment has been made by Jonathan Bixby, through Pioneer Media Holdings Inc. In addition to the Placing, Derek Lew, a director of the Company has invested £17,500 by electing to received accrued director’s remuneration in shares at the Placing Price.
The Company advises that it has made an investment of CDN$ 100,000 (approximately £57,000) into mobile gaming by way of an investment in 1182533 B.C. Ltd. (trading as Leaf Digital Studios) . Leaf owns a catalogue of available and to be launched mobile games. Caprice Business Developments Canada Inc., a TSX Venture Exchange listed company, is in the process of completing an acquisition of Leaf and subsequent readmission to the TSX Venture Exchange.
Salt Lake Potash 20p £58.9m (AIM:SO4)
SO4 has received binding commitments for a successful share placement to existing and new institutional shareholders and investors to raise A$20.0 million.
§ SO4 will issue 58.8 million new ordinary shares at A$0.34 each to raise gross proceeds of A$20 million (Placement).
§ The Placement further strengthens SO4’s share register with strong demand from existing institutional shareholders.
§ The funds will enable SO4 to continue to deliver the Lake Way Project to schedule, with commissioning expected in December 2020 and first production in Q1 2021.
4d Pharma 38.1p £41.7m (AIM:DDDD)
Prof. Dr. med. Axel Glasmacher has been appointed as Non-Executive Chairperson of the Board, with immediate effect.
Prof. Dr. med. Axel Glasmacher joined the Board of 4D Pharma as a Non-Executive Director in January 2019. Previously, he was Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he worked in various global roles for more than ten years.
Separately—publication of interim analysis of Blautix phase II study data. The interim analysis demonstrates that Blautix has a safety profile comparable to placebo, with 3% vs 2% patient discontinuation in the drug group vs. placebo due to adverse events . The interim analysis of the primary endpoint of the IBS study (shows that the study is not futile and 4D pharma plc is encouraged to continue the analysis of the full trial data.
Gfinity 1.25 £6.7m (AIM:GFIN)
The esports and gaming solutions provider, announces it has been selected by premier cricket broadcaster Willow TV (owned by the Times Group) to design and deliver “The eCricket Challenge”, in partnership with Betway. “The eCricket Challenge” is a TV series that will see some of the biggest names in world cricket competing against each other in the video game Cricket 19.
Gfinity designed and developed “The eCricket Challenge” format where players compete remotely in five-over matches. Through leveraging Gfinity’s virtual gaming expertise, cricket superstars from across three continents, were connected for real-time live games. The pre-recorded shows, hosted from the Gfinity Esports Arena in Fulham, London will premiere in the U.S. and Canada, with new episodes every Sunday starting on 19 April 2020.
“The eCricket Challenge” features global superstars including Jofra Archer, Stuart Broad and Liam Plunkett representing England, Kieron Pollard, Jason Holder, and Andre Fletcher joining from West Indies and Glenn Maxwell playing for Australia.
ECSC 67.5p £6.14m (LON:ECSC)
Placing of £0.5m at 0.55p. 31.8% discount to yesterday’s close. The Placing was subscribed to by both new and existing investors.
· The Company intends to use the net proceeds of the Placing as follows:
– to ensure the Company is sufficiently well capitalised to take advantage of longer-term growth opportunities once the COVID-19 situation stabilises; and
– to strengthen the balance sheet amidst the uncertainty caused by the COVID-19 pandemic in order to reassure clients.
Angle 55p £95m (AIM:AGL)
The liquid biopsy company, announced that the University of Athens has published results of new work undertaken in head and neck squamous cell carcinoma (HNSCC) demonstrating the use of ANGLE’s Parsortix® system in the analysis of gene expression and epigenetic alterations (DNA methylation markers) on circulating tumor cells (CTCs) from a simple blood test.
The results demonstrated that the Parsortix system had key advantages including:
· much higher CTC harvesting positivity rates;
· higher purity samples with lower levels of non-specific contaminant cells;
· excellent RNA quality for molecular analysis;
· higher relative expression levels for key cancer genes, including PDL1, which is a key target for immunotherapy drugs especially in this type of cancer;
· significantly higher proportion of samples testing positive for epigenetic alterations in CTCs (DNA methylation markers), which is a key area for cancer investigation.
*denotes a corporate client of Hybridan
Published at Fri, 17 Apr 2020 13:51:00 +0000-Small Cap Wrap –